Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 31774462.
- Also identified by DOI 10.1001/jamaoncol.2019.5098 and PMC identifier 6902180.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This case-control study examines the association of <i>Listeria monocytogenes </i>susceptibility with the receipt of daratumamab-based therapy in Canadian patients with multiple myeloma.
Medical subject headings
- Antibodies, Monoclonal
- Antineoplastic Agents
- Listeriosis
- Multiple Myeloma